S

Systimmune

Develops bispecific antibodies and ADCs

Medical Writer

Technical WritingConfirmed live in the last 24 hours
Full-timePrinceton, NJ, USA$80k - $130k /yrIn-person

About the Job

Requirements

  • A master's degree in a life sciences discipline, or at least 3 to 4 years of experience as a medical writer in the pharmaceutical industry; alternatively, a PhD with at least 1 year of medical-writing experience in the pharmaceutical industry.
  • Excellent writing skills.
  • Knowledge of FDA and ICH guidelines.
  • Skill in clinical data interpretation.
  • Proven experience writing or supporting major documents, including protocols, CSRs, ISE, ISS, and Clinical Overview documents.

Responsibilities

  • Write, edit, and/or manage the production of high-quality clinical documentation, including clinical study protocols, synopses, and clinical study reports for submission to regulatory authorities in support of marketing applications and BLAs.
  • Act as a member of clinical trial teams.
  • Follow and track clinical documentation milestones.
  • Write or edit other strategic documents as required.

Desired Qualifications

  • Knowledge of drug development and regulatory requirements to guide document organization.
  • Project management experience, including the use of negotiation and influence to ensure document timelines are met while maintaining high quality.

About the Company

Systimmune

Develops bispecific antibodies and ADCs

Systimmune is a biopharmaceutical company that develops antibody-based cancer therapies, including bispecific and trispecific antibodies and antibody-drug conjugates (ADCs). These products are designed to act on the solid tumor micro-environment to directly attack tumors and/or to activate the immune system to fight cancer. The company uses multiple immuno-oncology platforms and experienced scientists to create biologics that intervene in the tumor environment in systematic ways. Compared with competitors, Systimmune emphasizes integrating several antibody-based modalities (bispecifics, trispecifics, and ADCs) and a deep focus on the solid tumor micro-environment, aiming to translate biological insight into targeted, immune-engaging therapies. The goal is to produce biologics that effectively modulate the tumor environment and mobilize the body's own immune response to destroy cancer cells.

Company size
11-50
Company stage
Not listed
Total funding
Not listed
Headquarters
Redmond, WA
Founded
2014

Recently Posted Jobs

Explore more opportunities at Systimmune

See more jobs